Singulair (Montelukast Sodium) - Summary

SINGULAIR SUMMARY

SINGULAIR®
(MONTELUKAST SODIUM) TABLETS, CHEWABLE TABLETS, AND ORAL GRANULES

Montelukast sodium, the active ingredient in SINGULAIR, is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT₁ receptor.

SINGULAIR is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older.

SINGULAIR is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older.

SINGULAIR NEWS HIGHLIGHTS

Media Articles Related to Singulair (Montelukast)

FDA Checks Into Singulair Suicide Risk
Source: MedicineNet montelukast Specialty [2008.03.28]

more>>

Published Studies Related to Singulair (Montelukast)

Pharmacokinetics and safety of montelukast oral granules in children 1 to 3 months of age with bronchiolitis. [2008.04]

Effects of exercise training and montelukast in children with mild asthma. [2008.03]

Pilot study of oral montelukast added to standard therapy for acute asthma exacerbations in children aged 6 to 14 years. [2008.01]

Effect of azelastine, montelukast, and their combination on allergen-induced bronchoconstriction in asthma. [2008]

A double-blind, placebo-controlled trial of montelukast in adult atopic eczema. [2007.10]

more>>

Clinical Trials Related to Singulair (Montelukast)

Exercise Induced Bronchospasm in Children [Completed]

A Pilot Study of Montelukast Sodium (Singulair) in Older Adults With Asthma or Chronic Obstructive Pulmonary Disease [Completed]

A Study of MK0476 in the Treatment of Asthma Patients Aged 2-5 Years [Completed]

Montelukast in Acute RSV Bronchiolitis [Completed]

First Step With Singulair® Therapy [Completed]

more>>